Intra-arterial Administration of Verapamil for the Prevention and Treatment of Cerebral Angiospasm

Acta Neurochir Suppl. 2020:127:179-183. doi: 10.1007/978-3-030-04615-6_28.

Abstract

From 2013 to 2017, at the Burdenko Institute of Neurosurgery, intra-arterial verapamil for treatment of cerebral vasospasm following intracranial hemorrhage after aneurysm rupture was administered to 35 patients (total 75 procedures). The age is from 8 to 77 years. All ruptured aneurysms were treated: in 26 cases with open approach-clipping-and in 9 cases with endovascular occlusion. The procedure was carried out from 0 to 11 days after the operation. Severity of spasm was assessed by angiography and TCDU. Efficacy of the administration was assessed by TCDU 1 h after the procedure and by clinical evaluation of the patient's condition. The dose of verapamil was 15-50 mg (on average 40 mg) per procedure/per carotid pool and depended on the data of TCDU and clinical and radiological picture. The procedure was performed repeatedly (1-5 times) according to the indications and depending on the patient's condition, with an interval of 24 h. The procedure was effective as a preventive measure for care of patients in the initial stage of cerebral ischemia and was ineffective with a formed focus of ischemia. Endovascular administration of verapamil for treatment of cerebral vasospasm is a safe technique which positively affects the overall recovery of such patients.

Keywords: Cerebral angiospasm; Intra-arterial administration of verapamil; Intracranial aneurysm; Subarachnoid hemorrhage; Verapamil.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aneurysm, Ruptured*
  • Child
  • Humans
  • Middle Aged
  • Subarachnoid Hemorrhage* / drug therapy
  • Subarachnoid Hemorrhage* / prevention & control
  • Treatment Outcome
  • Vasodilator Agents* / therapeutic use
  • Vasospasm, Intracranial* / drug therapy
  • Verapamil* / therapeutic use
  • Young Adult

Substances

  • Vasodilator Agents
  • Verapamil